Interventional chemoembolization through hepatic artery and superior mesenteric artery for primary hepatocellular carcinoma：a control study of 21 cases
10.3969/j.issn.1008-794X.2014.08.017
- VernacularTitle:经肝动脉、肠系膜上动脉双途径治疗原发性肝癌21例对照研究
- Author:
Hao TIAN
;
Hao XU
;
Shixue WANG
;
Dongliang MAO
;
Zhaoxiang JIANG
- Publication Type:Journal Article
- Keywords:
primary hepatocellular carcinoma;
hepatic artery chemoembolization;
FOLFOX4 regimen;
superior mesenteric artery perfusion chemotherapy
- From:
Journal of Interventional Radiology
2014;(8):721-724
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy, the toxicity and side reactions of interventional chemoembolization with FOLFOX4 regimen through both hepatic artery and superior mesenteric artery, i.e. dual access technique, in treating primary hepatocellular carcinoma. Methods Between November 2010 and March 2013 at authors’ hospital, a total of 21 patients with advanced primary hepatocellular carcinoma (the study group) were treated with FOLFOX4 regimen by using dual access interventional technique. FOLFOX4 regimen included hepatic arterial infusion of 5-fluorouracil 400 mg/m2, hepatic arterial chemoembolization with iodipin and oxaliplatin 85 mg/m 2, intravenous administration of calcium folinate 200 mg/m2 IV on the first and second day, trans-superior mesenteric artery continuous infusion (lasting for 22 hours) of 5 -Fuorouracil 600 mg/m2 on the first and second day. During the same period other 21 patients with primary hepatocellular carcinoma were selected (used as the control group) to receive conventional hepatic arterial chemoembolization. In both groups, the treatment was repeated after 4-6 weeks. The therapeutic effect and the toxicity and side reactions were evaluated after the second treatment. Results The effective rate for the study group and the control group was 61.9% and 28.6% respectively, and the median survival time for the study group and the control group was 14.7 months and 9.4 months respectively. The differences in the effective rate and the median survival time between the two groups were statistically significant (P = 0.030 and P = 0.034). The occurrence of toxicity and side reactions, such as digestive tract reactions and the damage of liver function, in the study group were strikingly lower than those in the control group. Conclusion Through dual approach of hepatic artery and superior mesenteric artery catheterization, interventional chemoembolization with FOLFOX4 regimen is outstandingly effective for primary hepatocellular carcinoma, meanwhile, the side effects are very slight.
